Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference
Ironwood reported $296.2M in revenue and $24.0M in net income for fiscal 2025.
See the full IRWD financial statements: income statement, balance sheet, cash flow and ratios, each column linked to its SEC filing.
Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference
Ironwood Pharmaceuticals will webcast a September 10 conference fireside chat for investors, with a replay available on its website.
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10th at 10:15 a.m. ET.
A live webcast of Ironwood’s fireside chat will be accessible through the Investors & Media section of the company’s website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood’s website following the conference.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (Nasdaq: IRWD) is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases. Ironwood is advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients who are dependent on parenteral support. In addition, Ironwood has been a pioneer in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Building upon our history of innovation, we keep patients at the heart of our R&D and commercialization efforts to reduce the burden of diseases and address significant unmet needs.
Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts, with a site in Basel, Switzerland.
We routinely post information that may be important to investors on our website at www.ironwoodpharma.com. In addition, follow us on X and on LinkedIn.
A GLP-2 analog is a lab-made version of the natural gut hormone glucagon-like peptide‑2 that stimulates intestinal growth and improves nutrient and fluid absorption. It matters to investors because medicines in this class can reduce or replace long-term feeding support for people with severe intestinal conditions, so clinical trial outcomes, regulatory approval, pricing and manufacturing scale can materially affect a drug’s commercial potential—think of it as a booster that helps the gut absorb more like new tissue.
parenteral supportmedical
Parenteral support is medical care that delivers nutrition, fluids or medications directly into a patient’s bloodstream or body tissues, bypassing the digestive system—think of it as feeding or hydrating someone through an IV rather than by mouth. Investors care because this service involves specialized products, durable revenue from long-term patient use, strict safety and reimbursement rules, and potential regulatory or supply risks that affect company earnings and growth.
short bowel syndromemedical
A chronic digestive disorder caused when a large portion of the small intestine is missing or not working, so the body cannot absorb enough nutrients and fluids from food. Investors should care because people with this condition often need long-term medical treatments, specialized nutrition or surgeries, and ongoing devices or drugs, creating sustained demand, higher healthcare costs, and opportunities for companies that provide therapies, supplies, or related services.
chronic idiopathic constipationmedical
Chronic idiopathic constipation is a long-lasting condition where a person has infrequent or difficult bowel movements and no identifiable medical cause; “idiopathic” means doctors cannot find a specific underlying disease. It matters to investors because it represents a sizable, persistent patient population and a steady market for treatments, diagnostics and clinical trials—think of it as a common plumbing problem that creates ongoing demand for better tools and services.
